Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Triple Reuptake Inhibitors (“Broad Spectrum” Antidepressants)

Author(s): Phil Skolnick and Anthony S. Basile

Volume 6, Issue 2, 2007

Page: [141 - 149] Pages: 9

DOI: 10.2174/187152707780363285

Price: $65

Abstract

The majority of antidepressants in current use inhibit the uptake of serotonin and/or norepinephrine. Drugs inhibiting the uptake of serotonin, norepinephrine and dopamine (triple reuptake inhibitors) may offer therapeutic advantages compared to single and/or dual reuptake inhibitors. This review provides a rationale for developing this class of compound and describes the results of preclinical and clinical studies with a family of triple reuptake inhibitors.

Keywords: Antidepressant, dopamine, serotonin, norepinephrine, biogenic, amines, depression


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy